Published in Infect Immun on August 01, 2011
Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl Trop Dis (2012) 1.28
Sequence-defined transposon mutant library of Burkholderia thailandensis. MBio (2013) 1.03
Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders. Front Cell Infect Microbiol (2012) 0.93
Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing a manno-heptose capsule. Clin Vaccine Immunol (2013) 0.90
Burkholderia vaccines: are we moving forward? Front Cell Infect Microbiol (2013) 0.90
Characterization of the Burkholderia mallei tonB Mutant and Its Potential as a Backbone Strain for Vaccine Development. PLoS Negl Trop Dis (2015) 0.83
Role of RelA and SpoT in Burkholderia pseudomallei virulence and immunity. Infect Immun (2012) 0.83
Phenotypic Characterization of a Novel Virulence-Factor Deletion Strain of Burkholderia mallei That Provides Partial Protection against Inhalational Glanders in Mice. Front Cell Infect Microbiol (2016) 0.82
Recombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders. PLoS One (2015) 0.77
Structural diversity of Burkholderia pseudomallei lipopolysaccharides affects innate immune signaling. PLoS Negl Trop Dis (2017) 0.75
Burkholderia pseudomallei Capsule Exacerbates Respiratory Melioidosis but Does Not Afford Protection against Antimicrobial Signaling or Bacterial Killing in Human Olfactory Ensheathing Cells. Infect Immun (2016) 0.75
Novel gain of function approaches for vaccine candidate identification in Burkholderia pseudomallei. Front Cell Infect Microbiol (2013) 0.75
Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol Rev (1972) 19.14
Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev (2005) 14.71
Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol (2006) 6.34
Melioidosis: the tip of the iceberg? Clin Microbiol Rev (1991) 5.95
Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants and molecular characterization of the flagellin structural gene. J Bacteriol (1997) 3.60
Intracellular survival of Burkholderia pseudomallei. Infect Immun (1996) 3.56
Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med (1995) 3.16
Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene (1990) 2.80
Bioterrorism: a clear and present danger. Nat Med (2001) 2.43
Genetic tools for select-agent-compliant manipulation of Burkholderia pseudomallei. Appl Environ Microbiol (2007) 2.40
Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis (2008) 2.24
Immunoglobulin class switching. Curr Opin Immunol (1996) 1.94
Biodefense-driven murine model of pneumonic melioidosis. Infect Immun (2003) 1.85
A Burkholderia pseudomallei type III secreted protein, BopE, facilitates bacterial invasion of epithelial cells and exhibits guanine nucleotide exchange factor activity. J Bacteriol (2003) 1.78
Genetic tools for allelic replacement in Burkholderia species. Appl Environ Microbiol (2008) 1.75
What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol (2009) 1.69
Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection. J Infect Dis (2005) 1.56
Development of signature-tagged mutagenesis in Burkholderia pseudomallei to identify genes important in survival and pathogenesis. Infect Immun (2006) 1.54
Burkholderia pseudomallei: animal models of infection. Trans R Soc Trop Med Hyg (2008) 1.48
Burkholderia pseudomallei type III secretion system mutants exhibit delayed vacuolar escape phenotypes in RAW 264.7 murine macrophages. Infect Immun (2008) 1.44
Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect Immun (1997) 1.43
Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment. Proc Natl Acad Sci U S A (2008) 1.43
Nucleotide sequence of the asd gene of Escherichia coli: absence of a typical attenuation signal. EMBO J (1982) 1.38
Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J Med Microbiol (2002) 1.37
Aerogenic vaccination with a Burkholderia mallei auxotroph protects against aerosol-initiated glanders in mice. Vaccine (2005) 1.36
Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infect Immun (2006) 1.35
A Burkholderia pseudomallei deltapurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists. Infect Immun (2010) 1.26
A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins. J Infect Dis (2006) 1.24
Identification of the aspartate-beta-semialdehyde dehydrogenase gene of Legionella pneumophila and characterization of a null mutant. Infect Immun (1998) 1.23
Protection from pneumonic infection with burkholderia species by inhalational immunotherapy. Infect Immun (2009) 1.14
Evaluation of live-attenuated Salmonella vaccines expressing Campylobacter antigens for control of C. jejuni in poultry. Vaccine (2009) 1.12
Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Trans R Soc Trop Med Hyg (2008) 1.11
Global map of growth-regulated gene expression in Burkholderia pseudomallei, the causative agent of melioidosis. J Bacteriol (2006) 1.11
Glyphosate resistance as a novel select-agent-compliant, non-antibiotic-selectable marker in chromosomal mutagenesis of the essential genes asd and dapB of Burkholderia pseudomallei. Appl Environ Microbiol (2009) 1.09
Molecular genetic analysis of the region containing the essential Pseudomonas aeruginosa asd gene encoding aspartate-beta-semialdehyde dehydrogenase. Microbiology (1997) 1.02
Stable, site-specific fluorescent tagging constructs optimized for burkholderia species. Appl Environ Microbiol (2010) 0.99
Engineering of tellurite-resistant genetic tools for single-copy chromosomal analysis of Burkholderia spp. and characterization of the Burkholderia thailandensis betBA operon. Appl Environ Microbiol (2009) 0.89
Cloning and characterization of the Neisseria meningitidis asd gene. Gene (1993) 0.85
Plasmid maintenance systems suitable for GMO-based bacterial vaccines. Vaccine (2005) 0.85
Elicitation of predictable immune responses by using live bacterial vectors. Biomol Eng (2001) 0.84
A 10-min method for preparation of highly electrocompetent Pseudomonas aeruginosa cells: application for DNA fragment transfer between chromosomes and plasmid transformation. J Microbiol Methods (2005) 6.02
A Tn7-based broad-range bacterial cloning and expression system. Nat Methods (2005) 4.66
mini-Tn7 insertion in bacteria with single attTn7 sites: example Pseudomonas aeruginosa. Nat Protoc (2006) 3.19
Francisella tularensis induces aberrant activation of pulmonary dendritic cells. J Immunol (2005) 2.79
An improved method for rapid generation of unmarked Pseudomonas aeruginosa deletion mutants. BMC Microbiol (2005) 2.53
Genetic tools for select-agent-compliant manipulation of Burkholderia pseudomallei. Appl Environ Microbiol (2007) 2.40
Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis (2008) 2.24
PBAD-based shuttle vectors for functional analysis of toxic and highly regulated genes in Pseudomonas and Burkholderia spp. and other bacteria. Appl Environ Microbiol (2008) 2.16
Lung environment determines unique phenotype of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol (2009) 2.10
Two aerobic pathways for the formation of unsaturated fatty acids in Pseudomonas aeruginosa. Mol Microbiol (2006) 2.05
In vivo evidence of Pseudomonas aeruginosa nutrient acquisition and pathogenesis in the lungs of cystic fibrosis patients. Infect Immun (2007) 2.03
The MexJK efflux pump of Pseudomonas aeruginosa requires OprM for antibiotic efflux but not for efflux of triclosan. J Bacteriol (2002) 1.76
Genetic tools for allelic replacement in Burkholderia species. Appl Environ Microbiol (2008) 1.75
Versatile dual-technology system for markerless allele replacement in Burkholderia pseudomallei. Appl Environ Microbiol (2009) 1.74
Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev (2005) 1.71
mini-Tn7 insertion in bacteria with multiple glmS-linked attTn7 sites: example Burkholderia mallei ATCC 23344. Nat Protoc (2006) 1.58
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. Antimicrob Agents Chemother (2010) 1.50
Pseudomonas aeruginosa-plant root interactions. Pathogenicity, biofilm formation, and root exudation. Plant Physiol (2003) 1.50
Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010. Emerg Infect Dis (2012) 1.48
Proteome analysis of extracellular proteins regulated by the las and rhl quorum sensing systems in Pseudomonas aeruginosa PAO1. Microbiology (2003) 1.46
Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther (2010) 1.45
Transcript amplification from single bacterium for transcriptome analysis. Genome Res (2011) 1.41
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 1.40
Structure of the Pseudomonas aeruginosa acyl-homoserinelactone synthase LasI. Mol Microbiol (2004) 1.40
Clinical evaluation of a single dose of immune plasma for treatment of canine parvovirus infection. J Am Vet Med Assoc (2012) 1.39
Identification and characterization of TriABC-OpmH, a triclosan efflux pump of Pseudomonas aeruginosa requiring two membrane fusion proteins. J Bacteriol (2007) 1.36
Single-copy chromosomal integration systems for Francisella tularensis. Microbiology (2009) 1.34
Molecular basis of rare aminoglycoside susceptibility and pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand. PLoS Negl Trop Dis (2009) 1.34
Method for regulated expression of single-copy efflux pump genes in a surrogate Pseudomonas aeruginosa strain: identification of the BpeEF-OprC chloramphenicol and trimethoprim efflux pump of Burkholderia pseudomallei 1026b. Antimicrob Agents Chemother (2006) 1.33
Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2005) 1.30
Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc Natl Acad Sci U S A (2011) 1.29
Substrate-dependent utilization of OprM or OpmH by the Pseudomonas aeruginosa MexJK efflux pump. Antimicrob Agents Chemother (2005) 1.29
A Burkholderia pseudomallei deltapurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists. Infect Immun (2010) 1.26
Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun (2005) 1.26
Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei. Front Microbiol (2011) 1.25
mini-Tn7 insertion in bacteria with secondary, non-glmS-linked attTn7 sites: example Proteus mirabilis HI4320. Nat Protoc (2006) 1.20
High-level triclosan resistance in Pseudomonas aeruginosa is solely a result of efflux. Am J Infect Control (2003) 1.18
Beta-ketoacyl acyl carrier protein reductase (FabG) activity of the fatty acid biosynthetic pathway is a determining factor of 3-oxo-homoserine lactone acyl chain lengths. Microbiology (2002) 1.16
In vivo Bioluminescence Imaging of Burkholderia mallei Respiratory Infection and Treatment in the Mouse Model. Front Microbiol (2011) 1.14
Proteomic analysis of colony morphology variants of Burkholderia pseudomallei defines a role for the arginine deiminase system in bacterial survival. J Proteomics (2011) 1.13
Metal ion binding properties and conformational states of calcium- and integrin-binding protein. Biochemistry (2004) 1.12
Benchtop and microcentrifuge preparation of Pseudomonas aeruginosa competent cells. Biotechniques (2002) 1.09
Glyphosate resistance as a novel select-agent-compliant, non-antibiotic-selectable marker in chromosomal mutagenesis of the essential genes asd and dapB of Burkholderia pseudomallei. Appl Environ Microbiol (2009) 1.09
Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection. Antimicrob Agents Chemother (2010) 1.08
Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology (2009) 1.08
Development of Burkholderia mallei and pseudomallei vaccines. Front Cell Infect Microbiol (2013) 1.08
Expression of resistance-nodulation-cell-division efflux pumps in commonly used Burkholderia pseudomallei strains and clinical isolates from northern Australia. Trans R Soc Trop Med Hyg (2008) 1.08
In vivo Himar1 transposon mutagenesis of Burkholderia pseudomallei. Appl Environ Microbiol (2008) 1.08
The Pseudomonas aeruginosa PsrA responds to long-chain fatty acid signals to regulate the fadBA5 beta-oxidation operon. Microbiology (2008) 1.07
Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res (2006) 1.07
Genome-wide SNP discovery in tetraploid alfalfa using 454 sequencing and high resolution melting analysis. BMC Genomics (2011) 1.07
Two-pronged survival strategy for the major cystic fibrosis pathogen, Pseudomonas aeruginosa, lacking the capacity to degrade nitric oxide during anaerobic respiration. EMBO J (2007) 1.07
A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J Immunol (2006) 1.06
Mini-Tn7 vectors as genetic tools for single copy gene cloning in Acinetobacter baumannii. J Microbiol Methods (2010) 1.02
In vitro activity of BAL30072 against Burkholderia pseudomallei. Int J Antimicrob Agents (2011) 1.01
A high-throughput, homogeneous, bioluminescent assay for Pseudomonas aeruginosa gyrase inhibitors and other DNA-damaging agents. J Biomol Screen (2007) 1.00
Construction of mobilizable mini-Tn7 vectors for bioluminescent detection of gram-negative bacteria and single-copy promoter lux reporter analysis. Appl Environ Microbiol (2013) 1.00
Construction of a broad-host-range Tn7-based vector for single-copy P(BAD)-controlled gene expression in gram-negative bacteria. Appl Environ Microbiol (2012) 1.00
Global reprogramming of transcription and metabolism in Medicago truncatula during progressive drought and after rewatering. Plant Cell Environ (2014) 0.99
Stable, site-specific fluorescent tagging constructs optimized for burkholderia species. Appl Environ Microbiol (2010) 0.99
Early interaction of Yersinia pestis with APCs in the lung. J Immunol (2005) 0.98
Does microbicide use in consumer products promote antimicrobial resistance? A critical review and recommendations for a cohesive approach to risk assessment. Microb Drug Resist (2013) 0.96
Numerical analysis and optimization of optical spectral characteristics of fiber Bragg gratings modulated by a transverse acoustic wave. Appl Opt (2007) 0.96
Vaccine-induced CD8+ T cell-dependent suppression of airway hyperresponsiveness and inflammation. J Immunol (2009) 0.93
Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders. Front Cell Infect Microbiol (2012) 0.93
Nasal Acai polysaccharides potentiate innate immunity to protect against pulmonary Francisella tularensis and Burkholderia pseudomallei Infections. PLoS Pathog (2012) 0.93
Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med (2007) 0.93
Molecular characterization of MexL, the transcriptional repressor of the mexJK multidrug efflux operon in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 0.92
Mini-Tn7 vectors as genetic tools for gene cloning at a single copy number in an industrially important and phytopathogenic bacteria, Xanthomonas spp. FEMS Microbiol Lett (2009) 0.92
Suppression of vaccine immunity by inflammatory monocytes. J Immunol (2012) 0.91
Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis. Vaccine (2009) 0.91
Multiple FadD acyl-CoA synthetases contribute to differential fatty acid degradation and virulence in Pseudomonas aeruginosa. PLoS One (2010) 0.91
An improved method for oriT-directed cloning and functionalization of large bacterial genomic regions. Appl Environ Microbiol (2013) 0.90
The suppression of hypoxia-inducible factor and vascular endothelial growth factor by siRNA does not affect the radiation sensitivity of multicellular tumor spheroids. J Radiat Res (2009) 0.90
One step engineering of T7-expression strains for protein production: increasing the host-range of the T7-expression system. Protein Expr Purif (2007) 0.90
Genetic characterization of pcpS, encoding the multifunctional phosphopantetheinyl transferase of Pseudomonas aeruginosa. Microbiology (2004) 0.90
Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies. Stem Cell Res Ther (2013) 0.90
The long-chain fatty acid sensor, PsrA, modulates the expression of rpoS and the type III secretion exsCEBA operon in Pseudomonas aeruginosa. Mol Microbiol (2009) 0.90
In vitro comparison of feline bone marrow-derived and adipose tissue-derived mesenchymal stem cells. J Feline Med Surg (2012) 0.89
Engineering of tellurite-resistant genetic tools for single-copy chromosomal analysis of Burkholderia spp. and characterization of the Burkholderia thailandensis betBA operon. Appl Environ Microbiol (2009) 0.89
Consumption of rice bran increases mucosal immunoglobulin A concentrations and numbers of intestinal Lactobacillus spp. J Med Food (2012) 0.89
Burkholderia pseudomallei known siderophores and hemin uptake are dispensable for lethal murine melioidosis. PLoS Negl Trop Dis (2012) 0.88
Immunoproteomic identification of bovine pericardium xenoantigens. Biomaterials (2008) 0.88
In vitro activity of cethromycin against Burkholderia pseudomallei and investigation of mechanism of resistance. J Antimicrob Chemother (2010) 0.88
Evaluation of intrarenal mesenchymal stem cell injection for treatment of chronic kidney disease in cats: a pilot study. J Feline Med Surg (2011) 0.88
Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis. Microbes Infect (2010) 0.88
Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses. Cancer Immunol Immunother (2009) 0.88
The BpeEF-OprC efflux pump is responsible for widespread trimethoprim resistance in clinical and environmental Burkholderia pseudomallei isolates. Antimicrob Agents Chemother (2013) 0.87